NASDAQ:MEDP - Medpace Stock Price, Price Target & More

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings (NASDAQ:MEDP) released its quarterly earnings data on Monday, February, 26th. The company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.01. The business earned $99.45 million during the quarter, compared to the consensus estimate of $97.25 million. Medpace had a return on equity of 10.55% and a net margin of 8.97%. The business's revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.35 EPS. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Medpace.

Medpace updated its FY18 earnings guidance on Monday, February, 26th. The company provided EPS guidance of $1.82 to $1.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.80. The company issued revenue guidance of $412 million to $428 million, compared to the consensus revenue estimate of $423.58 million.

8 brokers have issued 1-year price objectives for Medpace's stock. Their predictions range from $35.00 to $42.00. On average, they expect Medpace's share price to reach $37.40 in the next year. View Analyst Ratings for Medpace.

Medpace saw a decrease in short interest during the month of March. As of March 15th, there was short interest totalling 426,813 shares, a decrease of 31.6% from the February 28th total of 624,254 shares. Based on an average daily volume of 257,372 shares, the days-to-cover ratio is currently 1.7 days. Currently, 5.0% of the company's stock are sold short.

Some companies that are related to Medpace include Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and Cleveland BioLabs (CBLI).

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

News stories about MEDP stock have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medpace earned a daily sentiment score of 0.23 on Accern's scale. They also assigned news headlines about the company an impact score of 44.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $36.64.

Medpace has a market capitalization of $1.34 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]